VSIG4 Monoclonal Antibody (NLA14), Super Bright™ 600, eBioscience™, Invitrogen™

Beschreibung

Description: This NLA14 monoclonal antibody recognizes mouse V-Set and Immunoglobulin domain containing 4 (VSIG4), also known as Complement Receptor of the Immunoglobulin superfamily (CRIg) or Z39Ig. VSIG4 is a type I transmembrane glycoprotein structurally related to the B7 family of immune regulatory proteins. It contains one complete V-type Ig domain and one truncated C-type Ig domain. VSIG4 is exclusively expressed on tissue resident and tumor infiltrating macrophages. It has been shown to bind complement components C3b and iC3b. This binding inhibits the alternative complement pathway and facilitates phagocytosis of complement-opsonized pathogens. VSIG4 has also been reported to suppress T cell activation, proliferation and IL-2 production thereby playing a role in the maintece of peripheral T cell tolerance and suppression of established inflammation. Expression of VSIG4 on tumor-infiltrating macrophages suggests its role in immune evasion. Pro-inflammatory stimuli such as TNF and LPS have been reported to down-regulate the expression of VSIG4. Peritoneal macrophages in Balb/c mice express significantly higher levels of VSIG4 than such macrophages in C57Bl/6 or Swiss Webster mice. The NLA14 antibody will recognize VSIG4 on cells that have been formaldehyde-fixed and permeabilized. This antibody does not block the ligation of VSIG4 to its T cell ligand. The NLA14 antibody does not cross-react with rat or human VSIG4.